{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.80","upperLimit":"23.8","value":"6.20"},{"groupId":"OG001","lowerLimit":"1.90","upperLimit":"23.6","value":"5.90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Characterize single and multiple-dose PK of LDK378 in pediatric patients. In this phase ceritinib was expanded at 500mg/m2 fed and 510mg/m2 fasted administered orally once daily and was assessed only at steady state, Cycle 2 Day 1.\n\nCharacterize single and multiple-dose PK of LDK378 in pediatric patients. Tmax: The time to reach maximum plasma concentration","dispersionType":"Full Range","groups":[{"description":"Participants in the fasted group who took 510 mg of ceritinib","id":"OG000","title":"Fasted: Ceritinib 510 mg/m2"},{"description":"Participants in the fed group who took 500 mg of ceritinib","id":"OG001","title":"Fed: Ceritinib 500 mg/m2"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set (PAS), MTD/RDE consisted of all patients who received at least one dose of ceritinib and had at least one evaluable PK sample.","reportingStatus":"POSTED","timeFrame":"0hr pre-dose, 2, 4, 6 & 24hrs post-dose","title":"PK Parameter: Tmax in Cycle 2 Day 1 - Dose Expansion Phase (Multiple Dose)","type":"SECONDARY","unitOfMeasure":"hour (hr)"}